XOMA Royalty Corporation recently declared quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will be receiving $0.53906 per share, while holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per depositary share. These dividends are set to be paid on or around October 15, 2024, to shareholders of record as of October 3, 2024. This move by XOMA demonstrates the company’s commitment to providing returns to its preferred stockholders.
XOMA Royalty Corporation is a biotechnology royalty aggregator that plays a unique role in assisting biotech companies in their mission to enhance human health. The company acquires potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology firms. When XOMA Royalty acquires these future economics, the seller receives non-dilutive, non-recourse funding that can be utilized to advance internal drug candidates or for general corporate purposes. With a portfolio containing over 70 assets, XOMA Royalty is dedicated to supporting advancements in the biotechnology and pharmaceutical industries.
The commercial assets in XOMA Royalty’s milestone and royalty portfolio include VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). It’s important to note that all other assets in the portfolio are investigational compounds, and there is no guarantee that they will become commercially available.
For more information about XOMA Royalty Corporation and its portfolio, interested individuals can visit www.xoma.com or follow the company on LinkedIn. By consistently providing dividends to its preferred stockholders and maintaining transparency in its operations, XOMA Royalty sets a standard for responsible corporate governance and investor relations.
